Medivation, Inc. (MDVN)
-NasdaqGS 48.86 
0.95(1.91%) May 24, 4:00PM EDT
| Prev Close: | 49.81 |
|---|
| Open: | 49.51 |
|---|
| Bid: | 48.86 x 100 |
|---|
| Ask: | 51.91 x 200 |
|---|
| 1y Target Est: | 68.88 |
|---|
| Beta: | 1.26 |
|---|
| Next Earnings Date: | 5-Aug-13 |
|---|
| Day's Range: | 48.32 - 49.75 |
|---|
| 52wk Range: | 39.62 - 59.24 |
|---|
| Volume: | 904,053 |
|---|
| Avg Vol (3m): | 1,239,040 |
|---|
| Market Cap: | 3.66B |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.93 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Astellas and Medivation Announce Submission of Application for Marketing Approval of Enzalutamide, an Oral Androgen Receptor Inhibitor, in JapanBusiness Wire(Fri, May 24)
- J&J: We're Creaming Medivation, Boehringer, Bristol And Pfizerat Forbes(Thu, May 23)
- Medivation's CEO Presents at UBS Global Healthcare Conference (Transcript)at Seeking Alpha(Mon, May 20)
- MEDIVATION, INC. FinancialsEDGAR Online Financials(Fri, May 17)
- Bayer's Xofigo Cleared in the USZacks(Thu, May 16)
- Bayer, Algeta Win U.S. Approval for Prostate Cancer Drugat Bloomberg(Wed, May 15)
- Does Dendreon Still Have Potential?at Wall St. Cheat Sheet(Tue, May 14)
- The 8 Biggest Health Problems Americans Faceat Motley Fool(Tue, May 14)
- Medivation Names Stephen Kelsey Senior Vice President of New ProjectsMarketwired(Mon, May 13)
- Energy And Biotechs With Recent Earnings Catalystsat Seeking Alpha(Mon, May 13)
- Medivation Loss Narrower Than ExpectedZacks(Mon, May 13)
- Medivation Inc. Stock Downgraded (MDVN)at TheStreet(Mon, May 13)
- MEDIVATION, INC. Files SEC form 8-K, Regulation FD DisclosureEDGAR Online(Sun, May 12)
- Investors are Digesting These Healthcare Stock Earnings Insightsat Wall St. Cheat Sheet(Sun, May 12)
- Dendreon: Picking Through the Carnageat Motley Fool(Sat, May 11)
Key Statistics
| Forward P/E (1 yr): | 77.56 |
|---|
| P/S (ttm): | 19.55 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.98 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.21 |
|---|
| Mean Recommendation*: | 1.7 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Medivation, Inc., a biopharmaceutical company, focuses on development and commercialization of novel therapies to treat serious diseases in the United States.
View More